General discussion, page-20277

Yes, unfortunately the "other general corporate purposes" alarmed not only myself but quite a lot of stakeholders. Funds from the CR is already scheduled for Asset Development and Coy Working and Admin costs. What other general corporate costs?? Ditution is through the roof now.

In relation to a "Class Action". In the past, from my experience a class action resulted in the director getting a wrap on the knuckles, fined $50-90k. (pocket change when salaries are in the millions) and shareholder walked away with nothing. Go figure when one director was found to mislead and cost many holders their portfolio.
A class action against Coy's/directors is never a good look and Mr Market will take note. Shee's where at 2cts aud....

Anyway patience and roll on Q4 and Dr Marks analytical trials report. This is what will change current sentiment and hopefully US investors and Institutional providers with these "deep pockets" come on board.